MarketPeel
Insider Trading Intelligence
Pricing
…
SP

Steve Pakola

RGNX
CHIEF MEDICAL OFFICER · REGENXBIO INC. · CIK 0001700659
FILING MIX · LIFETIME48%/52%
BUYS
16
SELLS
17
TOTAL VALUE
$3.01M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
249,734
AVG SELL PX
$14.53
TRADE KIND
SHOWING 33 / 33
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 8 pending
Forward-return performance of every backtestable P/S trade by Steve Pakola, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%-16.22%+0.50%-16.72%-13.86%—
14d6+83.33%-17.17%-0.16%-13.04%-17.57%—
30d6+83.33%-19.56%+2.03%-21.60%-23.44%—
60d6(1 pending)+40.00%-2.30%+3.19%-5.49%-2.36%—
90d6(1 pending)+50.00%-8.38%+5.71%-13.29%-7.51%—
180d6(2 pending)+100.00%-30.45%+6.68%-37.13%-40.33%—
1y6(2 pending)+100.00%-46.64%+12.18%-58.83%-64.05%—
2y6(2 pending)+100.00%-50.09%+35.90%-86.00%-85.32%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RGNX · 249,734 shares · as of Jul 1, 2026
064,579129,159193,738258,317202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 16 buys / 17 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RGNX
REGENXBIO INC.
PURCHASE
Chief Medical Officer
36,725$7.86$288.7K249,734Jul 1, 2026Jul 1, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
36,725——66,973Jul 1, 2026Jul 1, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
36,725$12.86$472.3K213,009Jul 1, 2026Jul 1, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
19,608$11.04$216.5K213,009Jun 29, 2026Jul 1, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE10b5-1
10b5-1 plan
15,309$11.02$168.7K232,617May 11, 2026May 13, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE10b5-1
10b5-1 plan
5,124$10.35$53.0K247,926Mar 10, 2026Mar 12, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
5,267$11.16$58.8K253,050Feb 1, 2026Feb 3, 2026 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
35,402——35,402Jan 6, 2026Jan 8, 2026 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
65,847——258,317Jan 6, 2026Jan 8, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
18,247$14.40$262.8K192,470Jan 2, 2026Jan 6, 2026 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
5,263$8.07$42.5K210,717Feb 1, 2025Apr 4, 2025 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
13,891$7.73$107.4K151,687Jan 2, 2025Jan 6, 2025 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
103,698——103,698Jan 2, 2025Jan 6, 2025 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
64,293——215,980Jan 2, 2025Jan 6, 2025 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
58,386——165,578Aug 1, 2024Aug 5, 2024 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
12,878——31,277Mar 5, 2024Mar 7, 2024 ↗View →
RGNX
REGENXBIO INC.
PURCHASE
Chief Medical Officer
12,878$22.25$286.5K120,070Mar 5, 2024Mar 7, 2024 ↗View →
RGNX
REGENXBIO INC.
SALE10b5-1
10b5-1 plan
12,878$28.36$365.2K107,192Mar 5, 2024Mar 7, 2024 ↗View →
RGNX
REGENXBIO INC.
SALE10b5-1
10b5-1 plan
17,237$17.39$299.8K107,192Jan 3, 2024Jan 4, 2024 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
32,051——124,429Jan 2, 2024Jan 4, 2024 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
50,875——50,875Jan 2, 2024Jan 4, 2024 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
10,385$17.95$186.4K92,378Jan 2, 2024Jan 4, 2024 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
90,588——102,763Jan 3, 2023Jan 5, 2023 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
44,155——44,155Jan 3, 2023Jan 5, 2023 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
1,837$22.68$41.7K15,313Jan 3, 2023Jan 5, 2023 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
3,138$22.17$69.6K12,175Jan 3, 2023Jan 5, 2023 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
1,598$33.75$53.9K8,250Jan 3, 2022Jan 4, 2022 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
8,900——17,150Jan 3, 2022Jan 4, 2022 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
42,500——42,500Jan 3, 2022Jan 4, 2022 ↗View →
RGNX
REGENXBIO INC.
SALE
Chief Medical Officer
1,152$32.70$37.7K9,848Jan 1, 2022Jan 4, 2022 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
11,000——11,000Jan 4, 2021Jan 6, 2021 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
49,700——49,700Jan 4, 2021Jan 6, 2021 ↗View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
42,600——42,600Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · RGNX
Loading peer insiders…
About this filer
CIK 0001700659
ROLE
Chief Medical Officer
PRIMARY
RGNX
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001700659DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback